MedTrace Logo

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2025-11-10

No results posted yet for this study

Summary

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).

The drugs involved in this study are :

* Abemaciclib (arm is currently closed to accrual)
* Temozolomide (temodar)
* Neratinib (arm is currently closed to accrual)
* CC115 (arm is currently closed to accrual)
* QBS10072S

Conditions

Interventions

DRUG

Temozolomide

Temzolomide capsules

DRUG

Neratinib

Neratinib tablets

DRUG

QBS10072S

QBS10072S administered intravenously

DRUG

Abemaciclib

Abemaciclib tablets

DRUG

CC-115

CC-115 tablets

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Celgene

    collaborator INDUSTRY

  • Puma Biotechnology, Inc.

    collaborator INDUSTRY

  • Accelerate Brain Cancer Cure

    collaborator OTHER

  • Quadriga Biosciences, Inc.

    collaborator INDUSTRY

  • Patrick Wen, MD

    lead OTHER

Principal Investigators

  • Patrick Y Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-09
Primary Completion
2028-02-01
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977780 on ClinicalTrials.gov